It is a privilege to participate in this Festschrift to honour Ian Simpson who has shown us the power of clinical thought in analysing a medical disorder as a biological problem. Among his many contribuitions, he has been widely applauded for his studies o'f myasthenia gravis, including an early analysis of thymectomy,l his introduction of the concept of myasthenia as an autoimmune disease,2 and the critical notion that pharmacological deductions about the physiological abnormality in myasthenia presumed normal morphological geometry at the endplate. 3 Simultaneously with Simpson's closely reasoned arguments, Nastuk and Strauss and their colleagues provided the first evidence of humoral abnormality4 and AG Engel and his colleagues provided evidence that the morphology of the endplate is not normal in human myasthenia. 5 It is my assignment in this symposium to review controversies about the therapy of myasthenia. Controversy is the unwanted child of ignorance, and we may be ignorant because we do not have the means to find the answers to questions, or because we have the means but cannot apply them. Too often in medicine, our ignorance seems to be due to asthenia of the will. We know how to find the answers, but we do not. We know that we could find out whether this or that proposed treatment is effective by setting up a controlled trial. But their own emotional problems; they want to treat. We adopt therapeutic programmes because they seem logical or useful, and these therapies become so embedded in custom that it is ultimately deemed unethical to even consider a controlled trial.
We are not alone in this dilemma. When I was a medical student, standard treatments included vagotomy for peptic ulcer and sympathectomy for hypertension; current controversies include radical mastectomy, tonsillectomy, carotid endarterectomy, and coronary by-pass surgery.6 7 Nevertheless, when physicians are entrusted with the care of patients with myasthenia gravis, they must choose between cholinergic drugs, steroids, more specific immunosuppressive drugs, plasmapheresis, and thymectomy. There is uncertainty about the value of all of these and there is difference of opinion about specific details of each therapy, or the sequence to be chosen. Lacking appropriate evidence, the physician must nevertheless make a choice.
That is the dilemma. Recognising that there are differences of opinion, I will try to make the questions clear, and to provide fair statements of divergent views. I have my own views, of course, but will try to separate assertion from fact.
CHOLINERGIC DRUGS
Little attention is being paid to cholinergic drug therapy for at least two reasons: First, these drugs do not ordinarily restore normal life to patients with myasthenia. Second, the apparent clinical benefit of immunot'herapies and evidence 644 of abnormal immune mechanisms in the disease have shifted therapeutic attention to measures that might alter the course of the disease, rather than merely reversing symptoms. Reviving archaic debates may not seem appropriate but almost all clinicians use anticholinesterase inhibitors to start treatment, and it may be useful to indicate that there are still unanswered questions, even about this primeval form of drug therapy. Which anticholinesterase medication is most effective? The immediate effects of cholinergic drugs are so dramatic that the therapeutic response can be considered part of the definition of the disease.8 There is no need for a controlled trial when ptosis disappears before your very eyes or ophthalmoplegia melts into normal motion. The therapeutic benefit of oral medication, however, is usually much less dramatic. Some disabled patients may be returned to normal activity, but symptoms are rarely relieved completely. Of the three drugs now available (neostigmine, pryridostigmine, ambenonium), pyridostigmine has proven the most popular, but this choice was never based on any kind of formal assessment. Rather, patients were asked which drug they preferred, and most chose pyridostigmine because it caused the fewest gastrointestinal effects. There has never been convincing evidence that one drug is better than another for specific symptoms, or that one drug can be effective when another is not. How is the optimal dosage of a cholinergic drug determined? There is still no way to determine the optimal dosage of pyridostigmine therapy, except by a trial that depends upon subjective responses of patient and physician. Osserman8 introduced the edrophonium test to determine optimal dosage. A patient already taking oral medication is given 2-0 mg edrophonium intravenously. If symptoms improve, the patient is deemed undertreated and the oral dosage is increased. If symptoms worsen, overtreatment is presumed and the oral dosage is decreased. If edrophonium has no effect, oral treatment is deemed optimal.
However, the edrophonium test has never been assessed formally, to determine whether these conclusions are justified. It was never demonstrated why 2 0 mg should be the decisive dose, rather than 3 0 or 5-0 or some other quantity, or why it should be the same in every patient. In untreated patients the same dose of edrophonium may have a diagnostic effect one day, no effect the next There are still, however, occasional references to the use of edrophonium as a method to determine whether weakness is "myasthenic" or "cholinergic". As originally described,8 the test again required an arbitrary dosage of edrophonium (1-0 or 2-0 mg), but interpretation now depended on only two choices: if weakness improved, it was "myasthenic"; if there was no improvement, or if weakness worsened, the weakness was "cholinergic". Again, however, this interpretation was never assessed formally, and it is not clear why "no response" should be deemed optimal in one situation but not in another. We have been sceptical about this interpretation because it has been standard practice in our institution for 30 One practical effect of this approach is that the distinction between "cholinergic" and "myasthenic" crisis becomes inconsequential, since the possibly offending drug is withdrawn anyway. It does, however, leave the question of when to resume drug therapy, and this is important after thymectomy as after crisis of other cause. There are no clear answers to this question but we view crisis as a temporary exacerbation; it is our task to keep the patient alive until the cause of the exacerbation subsides, assuming that it is due to transient effects of respiratory infection, aspiration pneumonitis, or surgery. Therefore, pyridostigmine does not seem useful and we cannot "get the patient off the respirator with pyridostigmine" while the patient is febrile, or while other complications are overtly active. Once these complications subside, respiration begins to improve and pyridostigmine can be started again. Could treatment be improved by monitoring blood levels of cholinergic drugs? Little is known about the pharmacokinetics of pyridostigmine. After intravenous injection of 14C-labelled drug, 44-47% of the administered label appeared in the urine within one hour." Because excretion of the drug exceeded creatinine excretion, there seemed to be tubular excretion as well as glomerular filtration.'2 13 Interactions with other drugs and hepatic meatabolism have not been defined, and much of orally administered drug appears in the faeces. '3 There have been few studies of blood levels since the introduction of gas-liquid chromatoLewis P Rowland graphy. In one study,'4 serum levels were lower in patients deemed "poorly controlled" than in those who seemed to be responding to therapy. Because parenteral administration of drug raised the low blood levels to the range of those in good control, the originally low drug levels were attributed to malabsorption. However, in another study,15 plasma pyridostigmine content was restricted to a narrow range 4153 54 The morbidity of this procedure is much less than the transsternal operation and it spares the patients from a disfiguring scar on the chest. The morbidity is so slight that the indications can be extended to children or the elderly, or to patients with only slight functional disability, groups not ordinarily selected for the trans-sternal operation.
Since the results of the transcervical operation are claimed to be equivalent to the standard procedure,33 4' 5 54 it is rather strange that the operation has not been adopted by more than one centre in the US and one in Europe.36 The major argument against the cervical approach has been stated by Jaretzki26; it is not possible to do a total thymectomy through the neck in every patient; complete removal of the thymus requires thorough exploration of the mediastinum. 55 59 This dispute will only be resolved by the results. What is needed is some evaluation of truly com,parable patients subjected to the two procedures and foSllowed for a prolonged period of observation; this is not available. If the cervical operation ultimately proves to be beneficial, it would mean that "total" thymectomy is not necessary for therapeutic effect. This conclusion is not impossible, since no one knows what deleterioas influence is removed by thymectomy, nor why improvement may be delayed as long as seven years; merely reducing the burden may suffice. Is it possible to predict which patients will benefit from thymectomy? Other controversies pale by comparison to the questions about thymectomy itself, or the surgical approach, but other differences of opinion should be noted. Originally, it seemed that young women were the best candidates for thy-mectomy, but this could have been an artefact of selection since young adult patients would be most likely to be selected for a major surgical procedure, and most young adult patients with myasthenia (and no thymoma) are women; some men and some older patients have improved in virtually every report. Short duration of symptoms has been deemed important, especially in recent years,29 3 66 There has been concern about doing thymectomies in pre-adolescent children67, but the rates of improvement seem no different from those in adults and no long-range harm has become evident, even when the operation was performed in children as young as two years. 45 68-74 It is probably fair to state that there are no reliable predictors of favourable outcome. The most common indication for thymectomy is disabling myasthenia, but "disabling" permits considerable room for subjective choice by the physician. As the operation becomes safer, and as more physicians become convinced of the value of the operation, more patients are selected for thymectomy and, increasingly, during the first year or two of symptoms.
Can "early" thymectomy prevent "progression" of myasthenia? Although it is difficult to find evidence in the literature, it has been stated that early thymectomy prevents "progression" of mild myasthenia to a severe state. 33 Negative views of the effects of corticosteroids were reinforced by two other early reports, one from the Mayo Clinic90 and the other from Johns Hopkins91; both papers were influential because the writers were such highly respected authorities on myasthenia. The Hopkins paper was especially powerful and the story was told in the title of the paper: a patient was being treated with cortisone for rheumatoid arthritis when symptoms of myasthenia first appeared. If a drug cannot prevent the first symptoms of a disease, how can it be effective in therapy?
As a result of these experiences, there were no reports of steroid therapy from any of the major myasthenia centres for more than a decade. There were still, however, occasional reports of benefit92 98 and this provided the background for a peculiar episode in the early 60s. At that time, several clinicians were concerned about the lack of controlled trials to evaluate thymectomy and they met to design a suitable protocol. The question of appropriate controls, however, seemed insurmountable; even then, the notion of sham operation was theoretically desirable but was deemed ethically impossible. Also, the cooperation of individualistic centres was difficult to achieve. To prepare for some kind of cooperative trial of thymectomy, therefore, the participants agreed to study the effects of ACTH on ocular myasthenia.
For several reasons, this seemed to be an ideal way to devise methods of cooperative investigation. Eye movements before and after therapy could be photographed and measured, objectively and quantitatively, without recourse to subjective evaluation and difficult-to-define words such as "improved". Evaluation could be completely "blind"; photographs were sent to another city and measurements were made without knowledge of therapy, whether it was placebo or ACTH, or even whether the photographs were taken before, during, or after therapy. Finally, because the patients had solely ocular symptoms and because the duration of therapy was limited, the patients were not being subject to any serious risk.
So the trial was initiated. Cooperation among the participating centres was excellent. The results were unequivocal. ACTH therapy, 580 units given in eight days, had no effect. 94 The 26 patients improved and three patients were in complete remission; the dosage was 2 mg/kg body weight. Improvement was not seen until after six to 12 weeks and the maximal effect appeared in six to 15 months. Because the "gradual effect makes it difficult to evaluate the effect properly", azathioprine was discontinued every year or two to determine whether there had been a spontaneous remission, but the results of this test were not stated. The drug had to be withdrawn because of agranulocytosis in only one patient. Sepsis and pneumonia affected two patients, one fatally.
Hertel et al'22 used 150-200 mg azathioprine without steroids, to treat 64 patients. Thirtythree patients were given the drug after thymectomy, so that the prolonged improvement included the effects of both treatments but they implied that azathioprine hastened or enhanced the results of thymectomy (although specific data were not given); four years after thymectomy, they were still improving. Very severe myasthenia was treated with both corticosteroids and azathioprine in 15 cases and all but one improved. Only one patient had severe bone marrow depression that lasted for several months, and therapy did not have to be discontinued in any patient because of hepatic or gastrointestinal toxicity. One patient died of sepsis and another had orchitis.
Reuther et al'24 studied AChR antibody resvonses in nine of the patients mentioned by Hertel et al'22; three had thymectomies. Titres declined to about 70% of the initial values by three years and to 40% after five years. Although all patients improved and seven were in remission, abnormal antibody titres persisted in all of them.
Newsom-Davis et al'25 gave azathioprine in a daily dosage of 2-5 mg/kg, to six patients; five had thymectomy and five were receiving prednisone. They were compared to seven patients who received the drug (concomitant with prednisone in four and who were also treated by plasma exchange. Six of the 13 patients improved in the observation period of four to 12 weeks, and all patients showed a decline in antibody titres, but there were no significant differences between the two groups. No serious side-effects were reported.
There have been reports of treatment with other immunosuppressive drugs that are not generally available126 or with antithymocyte globulin'27 128 but the numbers of patients were too small to evaluate critically.
Since 1970, there has been one major change; there is now a clear rationale for the use of immunosuppressive drugs. Because of a single Lewis P Rowland law-suit in the United States, there has been little experience with these drugs in this country. As in 1970, the reports of azathioprine seem promising. As in 1970, there has been no controlled trial of effects that only appear gradually. Three deaths have been attributed to azathioprine or its metabolite, mercaptopurinel20 123 129 but it is not known whether azathioprine is more or less hazardous than prednisone, whether it should be given alone or in combination with prednisone, or whether it improves the results of thymectomy alone. Even the proper dosage is uncertain. That is, it is not clear whether an arbitrary dosage of 2-5 mg/kg is appropriate for all patients or whether the dosage should be increased to cause mild leucopenia as evidence of biological effect (but, presumably, with increased risk). The situation is not tidy.
PLASMAPHERESIS
That myasthenia might be an autoimmune disorder was first suggested by Smithers in 1959130; the theory captured attention after the seminal paper of Simpson2 and the demonstration of antibodies to muscle striations by Strauss et a14 in 1960. By the end of the decade, however, there was much uncertainty because the striation-binding antibodies were lacking in most cases, could not explain the disorder of neuromuscular transmission, and could not be demonstrated consistently in neonatal myasthenia. Attention was therefore being directed to alterations of cell-mediated immunity, when the first attempts were made in 1969 to remove immunopathogens from the myasthenic patient. Since cell-mediated mechanisms were suspected, it was therefore surprising that the benefits of thoracic duct drainage seemed to be due to something in plasma rather than the lymphocytes.131 132 In retrospect, another observation of that time could have been due to removal of plasma, for an infant with neonatal myasthenia improved promptly after an exchange transfusion for Rhincompatibility. '33 These early observations made more sense a few years later, after the elucidation of experimental autoimmune myasthenia and the demonstration of antibodies to AChR in human patients. The technology of human blood separation had also advanced and it was therefore logical to attempt to remove the pathogenic antibodies by plasma exchange, or plasmapheresis. 
